[The clinical significance of determining the HLA-DR4 antigen in patients with breast cancer].
A study of HLA phenotype in 151 cases of breast cancer showed an increased occurrence of DR4 antigen (46.8%) as compared to general population (16.3%). Some clinical parameters of DR4-positive and DR4-negative patients were compared. Estradiol receptor-negative tumor was observed in 40% of DR4-positive patients and only in 18.5% of estradiol receptor-negative ones. DR4 positivity was associated with poorer prognosis.
Iarygin
L M
LM
Malyshev
V S
VS
Polianskaia
I S
IS
Denisov
L E
LE
Zimin
Iu I
IuI
Alekseeva
P L
PL
Khotchenkova
N V
NV
D000368:Aged; D001943:Breast Neoplasms / Q000737:chemistry / Q000276:immunology*; D005260:Female; D015804:HLA-DR4 Antigen / Q000032:analysis*; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
D015804:HLA-DR4 Antigen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
Klinicheskoe znachenie opredeleniia antigena HLA-DR4 u bol'nykh rakom molochnoĭ zhelezy.